Skip to main navigation Skip to search Skip to main content

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date10/10/18 → 10/1/24

Funding

  • Celgene International II Sarl: $68,007.00